June 11, 2007 — Cardio BioSciences and Mayo Clinic announced today that they have entered into a collaborative agreement related to the licensing of Mayo Clinic research, know-how and intellectual property in the field of cardiac commitment of stem cells, in a move that positions Cardio_ BioSciences as a global leader in the field of regenerative therapies for heart failure
The research, headed by Andre Terzic, MD, PhD and Atta Behfar, M.D., at Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.
“This opportunity positions Cardio BioSciences as a global leader in the field of regenerative therapies for heart failure,” said Christian Homsy, MD, CEO of Cardio_ BioSciences. “The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.”
“Over one million Americans suffer a new or recurrent heart attack each year. Despite the aggressive approaches we use to treat heart patients, no effective means are available to repair a damaged heart,” added Terzic. “Discoveries by the Mayo team open new therapeutic avenues exploiting the regenerative potential of stem cells guided toward cardiac lineage. We are excited about translating this novel methodology into repair strategies.”
For more information: www.cardio3bio.com and www.mayoclinic.com
November 19, 2021 
